Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-104: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre First-in-man Study in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2018
Price :
$35
*
At a glance
- Drugs ODM 104 (Primary) ; Entacapone; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Biomarker; First in man; Pharmacodynamics
- Acronyms NOCIFIM
- Sponsors Orion; Orion Pharma
- 19 Jun 2018 Primary endpoint has been met. (Erythrocyte Catechol-O-methyltransferase (COMT) inhibition.)
- 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology
- 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology